THE DEAL, AT A GLANCE
From the announcementILiAD Biotechnologies
01Who is involvedBacked by RA Capital ManagementFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedILiAD Biotechnologies raised $115M Series BFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersILiAD Biotechnologies is using a $115M Series B financing to advance BPZE1 pertussis vaccine development in Healthcare & Life Sciences.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
ILiAD Biotechnologies · Financing Record
Explore source-linked visual explanations for ILiAD Biotechnologies. Unsupported claims are withheld while source review continues.
Record 2274 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →